Researchers ‘turbocharge’ vaccine delivery by jolting ‘bystander’ immune cells into action in animal models
Posted: 25 September 2024 Monash University researchers have developed a new technique to boost the effectiveness of both traditional and mRNA-based vaccines in animal models. Published in Immunity, the study found that adding low doses of vaccine-specific antibody to…
Telix to acquire RLS to expand North American manufacturing and distribution platform
Posted: 25 September 2024 Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The…
PAT-DX1 GMP specification testing update
Posted: 23 September 2024 Patrys Limited, a therapeutic antibody development company, provides the following update regarding the recently completed GMP manufacturing run of PAT-DX1. Patrys’ Contract Development Manufacturing Organisation (CDMO) has advised the Company that the Quality Assurance…
Tumour response in sixth patient triggers additional recruitment in pancreatic cancer trial
Posted: 23 September 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved…
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
Posted: 23 September 2024 Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models…
FDA Fast Track Designation For Narmafotnib in Advanced Pancreatic Cancer
Posted: 23 September 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib,…
Major $21m Colonial Foundation philanthropic investment to bring future science into disease diagnosis
Posted: 23 September 2024 An outstanding $21 million philanthropic investment will establish a pioneering research centre to advance precision diagnosis for diseases that affect millions of Australians. The Colonial Foundation Diagnostics Centre will use cutting-edge ‘spatial biology’ technologies…
$34 million for research into stem cell therapies for osteoarthritis and other conditions
Posted: 18 September 2024 The Australian Government is investing $34.5 million in research funding to trial new treatments and therapies aiming to harness the power of stem cells to improve patient outcomes. Research advances over the past 10…
New digital innovation partnership
Posted: 17 September 2024 La Trobe University has welcomed the Victorian Government’s announcement that an industry-led consortium comprising Artesian Capital Management, La Trobe University, University of Melbourne and RMIT University has been selected to establish the Cremorne Digital…
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Posted: 17 September 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb…
Vale Leon Serry, AM
Posted: 13 September 2024 The contributions of biotechnology industry leader Mr Leon Serry, AM are being recognised by BioMelbourne Network as it acknowledges the passing of a steadfast supporter of our sector and of BioMelbourne Network and its…
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
Posted: 13 September 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an update on…
